Only 200,000 of 250 million obese on GLP 1, Says Novo Nordisk as semaglutide Patent expires
As semaglutide went off-patent in India on March 20, innovator drugmaker Novo Nordisk said the market remains largely…
Novo Nordisk rules out price war as semaglutide generics enter India | Company News
With the patent on blockbuster obesity and diabetes drug semaglutide set to expire in India within days,…
Abbott and Novo Nordisk partner to launch Extensior for diabetes care in India
India’s diabetes challenge is growing fast, and access to modern treatment options matters more than ever. In a…